Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types.
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Objectives: To develop a multiplexed pseudovirion-based serological assay (PsV-Luminex) encompassing 21 HPV types and validate the method by correlating the serology with the presence of type specific HPV DNA in cervical samples. Results: On average 51 % of the HPV DNA positive women were seropositive for the same HPV type that was detected in the cervical specimen. We found a strong correlation with presence of HPV DNA and antibodies to the same HPV type for 13/15 genital HPV types (median OR=5.7,CI 95%= 2.4-12.9). HPV-52 serology failed the validation and HPV-11 serology could not be validated because only a single woman was positive for HPV-11 DNA.
The correlation between serology and HPV DNA status tended to be stronger among women infected with single HPV type (median OR=10.5,CI 95%=2.4-48.4) than among women with multiple HPV infections (median OR=4.6,CI 95%=1.8-11.7).
Conclusions:
A multiplexed HPV PsV-Luminex assay has been developed and validated to correlate with natural HPV infection for 13 HPV types, thus enabling more comprehensive studies in HPV epidemiology and vaccine research.
Background
Persistent human papillomavirus (HPV) infection is established as a necessary cause for almost all cases of cervical cancer as well as for a proportion of vulvar, vaginal, penile, anal and oropharyngeal cancers (1, 2) . Two highly effective vaccines are available against the two most oncogenic HPV types, HPV-16-and -18 (3, 4) . However, there is still intensive research on HPV prophylactic vaccines as the exact mechanism of vaccine protection is not known (5) and as second-generation, multivalent HPV vaccines are under development (6) .
Most genital HPV infections are transient and clear within 6-12 months (7) . Therefore, HPV DNA testing cannot measure cumulative HPV exposure. Although not all HPV infections lead to seroconversion (8, 9) , the antibody responses to the HPV capsid are known to be stable over time (also after clearance of HPV DNA) providing a useful measure of cumulative HPV exposure (10) .
Most HPV serology studies performed to date have been restricted to HPV-16 and -18 (11) , although some studies have also reported on seropositivity to other HPV types (12, 13) .
Multiplexed serology is a high-throughput method that could make it possible to study the seroepidemiology of multiple HPV types more routinely. So far, most multiplexed HPV serology studies have used GST-L1 fusion proteins as antigen (11) . The type-specific antibody response to HPV is predominantly against conformational epitopes that are exposed on native virions, but not on disrupted virions. We have previously developed and validated a high-throughput, multiplexed HPV serology method based on mammalian cell-produced HPV pseudovirions (PsVs) for 10 HPV types (PsV-Luminex) (14). In the present study, we have expanded this method to include pseudovirions from 21 HPV types and 2 polyomaviruses (merkel cell polyomavirus (MCV) and JC polyomavirus (JCV)). Validation of HPV serology for the less common HPV types is a challenge, as very large cohorts with both serum sampling and reliable HPV DNA testing are required in order to obtain sufficiently large validation panels. We used a population of 3,291 women who had already been tested for presence of HPV DNA status for 15 genital HPV types (15, 16) to evaluate the performance of our extended multiplexed serology assay.
Objectives
To develop an expanded multiplexed HPV serological assay based on HPV pseudovirions and to evaluate the performance of the assay by comparing serology with HPV DNA status.
Study design

Study populations
In the present study, 3,321 women 20-64 years of age (average age 36 years) who participated in the National Cervical Cancer Screening Program (DP ZORA) in Slovenia were consecutively enrolled into the Slovenian HPV Prevalence Survey (SHPVPS) (15, 16) . From each consenting participant, both a cervical smear and a blood sample were collected.
Collection of cervical smears is described in detail elsewhere (16) . Whole blood samples (5 mL) were stored at +4 °C for less than a week before centrifugation for 5 min at 3,000 rpm.
The serum was aliquoted and stored at -30 °C until further analysis. Thirty women who had been vaccinated against HPV were excluded.
Two negative control serum panels were included: serum samples from 133 Swedish children not older than 12 years of age (average age 6 years) (17) and 71 serum samples from adult HPV DNA testing HPV DNA testing and genotyping is described in detail elsewhere (15) . Briefly, cervical samples were tested in parallel with Hybrid Capture 2 HPV DNA Test (hc2) (high-risk probe cocktail B) (Qiagen, Hilden, Germany) and RealTime High Risk HPV Test (RealTime;
Abbott, Wiesbaden, Germany). All samples with concordant positive RealTime/hc2 results and all samples with discordant RealTime/hc2 results were further analyzed with the Linear Array HPV Genotyping Test (Linear Array; Roche Molecular Diagnostics, Branchburg, NJ), with an HPV-52 type-specific real-time PCR assay (INNO-LiPA HPV Genotyping Extra Test (Innogenetics, Ghent, Belgium)) and, if necessary an in-house GP5+/GP6+ PCR assay. In addition, 1,000 randomly selected samples were also tested for the presence of 37 HPV genotypes with Linear Array HPV Genotyping Test (Učakar et al., manuscript in preparation).
Since the hc2 and RealTime assays do not include detection of HPV types -6, -11 and -73, the comparison of DNA prevalences and seroprevalences of these types were calculated only for samples that were tested with Linear Array HPV Genotyping Test and INNO-LiPA.
Serological HPV testing
Serology was performed as described (14).To minimise inter-assay variability, the antigens were produced in large batches that were bound to the beads, aliquoted and frozen until testing. We produced pseudovirions for 17 HPV types belonging to species alpha: 3, 6, 11, 
Statistics
Odds ratios (OR) and 95 % confidence intervals (95 % CI) were estimated using the Statcalc module of Epi-info version 3.5.1 (shareware available at www.cdc.gov).
Results
In the control group of 133 children, the HPV antibody prevalence did not exceed 4% for any studied HPV type (Table 1 ). In the groups of adult women, HPV-16 had the highest seroprevalence (14.1 % in the control group of 71 women with ≤1 lifetime sexual partner and 25.2 % in the SHPVPS study population of 3,291 women). Among women with ≤1 lifetime sexual partner, seropositivity for more than one genital HPV type was uncommon (15.5 % positive for >1 type, 29.6 % positivity for a single type), whereas in the SHPVPS population seropositivity to multiple genital HPV types was more common (44.3 % positive for >1 genital type, 21.5 % positivity for a single type). Seropositivity for cutaneous HPV types was mostly found as seropositivity for only a single HPV type, in all studied populations.
HPV DNA status was available for 3,270 women from the SHPVPS study population. Among these, 515 were positive for at least 1 HPV type and out of these, 262 were positive for multiple HPV types. Among HPV DNA positive women, 51% (range 15-100 %) had antibodies to the same HPV type detected with PsV-Luminex method ( Table 2) . By comparison, among HPV DNA negative women 9% had antibodies to a particular HPV type and among women HPV DNA positive to some other genital HPV, 16% had antibodies to particular HPV type. The 9% seroprevalence among currently HPV-negative women does not necessarily constitute false positives, as women may have had previous HPV infections. The somewhat higher seroprevalence (16%) among subjects positive to another HPV type than the one tested for should not be interpreted as suggesting crossreactivity between HPV types, as the HPV types share the same mode of transmission. Previous studies validating HPV ELISA found that adjustment for sexual history explained most of the difference in seroprevalence between HPV-negatives and women positive for HPV DNA of another type (18) . The median OR for association between HPV DNA and seropositivity to the same HPV type was 5.7 (CI 95 % 2.4-12.9) ( Table 2) . Only for HPV-52 was seropositivity not significantly associated with HPV DNA status (OR=1.8, CI 95 % 0.9-3.7). Only one woman was positive for HPV-11 DNA and evaluation of the HPV-11 serology was therefore not possible. The associations between DNA status and seropositivity tended to be stronger among women with a single HPV DNA infection (median OR=10.5, CI 95 % 2.4-48.4), compared to women with multiple HPV DNA infections (median OR= 4.6, CI 95 % 1.8-11.7). For HPV-59 the association was stronger for multiple infections and for HPV-16, there was no difference between single and multiple HPV infections.
were seropositive for at least one genital HPV type (Table 3 ). Of these, 81/175 (46%) had antibodies both to the HPV type that was present in the cervix and to at least one other genital HPV type. Seropositivity for the HPV type present in the cervix, but not to any other genital HPV type was found in only 14/175 (8 %) of these women. Seronegativity for all studied genital HPVs was present in 23/175 (13%) of these women and 57/175 (33 %) were positive for antibodies to another genital HPV type than the one present in the cervix.
Discussion
We have developed and validated a high-throughput serology method that contains the largest array of native HPV antigens (pseudovirions) so far described. Comprehensive HPV DNA testing of cervical swabs in a large number of women attending the cervical cancer screening program who participated in SHPVPS enabled us to evaluate the association of HPV type specific seroreactivity to the presence of cervical infection with the same HPV type, also for relatively uncommon HPV types.
Compared to our previous study (14), our method has a lower inter-assay coefficient of variation and an increased sensitivity. Since this study involved testing of several thousand serum samples and because activated Luminex beads are not recommended to be stored at +4 °C for more than 1 month, we had to change testing procedure. Rather than activating smaller amounts of beads many times, we chose to bind antigens sufficient for the entire study to the beads and freeze aliquots at -80 °C. The only antigen that appeared to be sensitive to freezethawing was JCV VLPs, where the coefficient of the variation was increased rather than decreased by the freezing. The improved sensitivity was largely attributable to the fact that cut-off values are calculated separately for every HPV type, using the international algorithm recommended by the WHO global HPV LabNet (20) .
We found a low seroprevalence for genital HPVs among children, as expected (14, 17, 21, 22) . The seroprevalence for MCV among children was around 30 %, which is also in agreement with other studies (23) . Seroprevalences of JCV and MCV in the adult Slovenian women were also similar (around 65 %) to other studies of European adults (24) .
The most commonly used method for HPV serology has been ELISA using HPV L1 VLPs, a method known to give comparable results to the PsV-Luminex method (14). Most ELISA studies have only used the HPV types included in the quadrivalent vaccine (HPV-6,-11,-16,-18) (11) . Our HPV-16 and -18 seroprevalences are similar to those reported in a multi-country European study (25) . The expected proportion of HPV DNA-positive women who have serum antibodies to the same type of HPV is around 50 % and this was also the case for most of the genital HPVs in the present study.
In our previous study, HPV-45 and HPV-52 PsV-Luminex did not perform adequately (14).
In the present study, the HPV-52 test was still inadequate, but the HPV-45 test was now adequate. Possible reasons for the improvement include that the HPV DNA status was ascertained by multiple tests, which could have resulted in better validity or that a new batch of HPV-45 pseudovirions was used. Regarding HPV52, we found that the pseudovirions reacted well with type-specific monoclonal antibodies and that antibodies to these HPV-52 pseudovirions were clearly associated with cervical cancer in a large case-control study from Thailand (Faust et al, unpublished observation). HPV-52 is known to cross-react with several other probes in the Linear Array assay and in international proficiency studies of HPV genotyping, HPV-52 has been one of the most frequently misclassified types, in particular in relation to the closely related type HPV-58 (26). However, we have no indication of any sort of technical problem with the HPV-52 genotyping in this study and it is uncertain whether the problem with HPV-52 lies in the serology or the genotyping. At any rate, validation of each new batch of pseudovirions using positive and negative control serum panels from carefully genotyped women appears to be highly advisable.
We found a tendency for HPV seropositivity to associate more strongly with presence of the same type of HPV DNA, if there was only one type of HPV DNA present in the cervix. This tendency is of interest as it might suggest that in case of a natural single HPV infection, the immune system might respond more precisely compared to infection with multiple HPV types. This would agree with the fact that vaccination with multivalent HPV vaccines have been found to induce "cross-reactive" antibodies (27) (28) (29) .
A limitation of our study was that the new HPV pseudovirions were not tested with neutralizing monoclonal antibodies to type-specific conformational epitopes to ensure that the pseudovirions adequately presented these epitopes. Another limitation was that we established HPV DNA status by testing cervical samples only resulting in that the assays for cutaneous HPV types could not be evaluated and that the HPV DNA status will have been underestimated, particularly forHPV-6 and-11, as these HPV types more frequently infect external genital sites than the cervix.
In conclusion, our expanded and validated high-throughput serology method using pseudovirions is likely to enable a more reliable use of comprehensive HPV serology in HPV vaccine research and studies of natural history and epidemiology of HPV. Table 1 . Seropositivity for HPV types and polyomaviruses in two control groups (Children ≤ 12 years and women with ≤1 lifetime sexual partner) and adult women participating in cervical screening. 
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